Loading...
Docoh

Teleflex (TFX)

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. The Company applys purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Its portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference.

Company profile

Ticker
TFX
Exchange
CEO
Liam Kelly
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
1902 Federal Road, LLC • Arrow Internacional de Chihuahua, S.A. de C.V. • Arrow Internacional de Mexico, S.A. de C.V. • Arrow International • Arrow Interventional, Inc. • Distribuidora Arrow, S.A. de C.V. • EON Surgical Ltd. • Essential Medical, Inc. • Hudson Respiratory Care Tecate, S. de R.L. de C.V. • Inmed Manufacturing ...
IRS number
231147939

TFX stock data

Calendar

28 Jul 22
9 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 308.12M 308.12M 308.12M 308.12M 308.12M 308.12M
Cash burn (monthly) 52.85M 4.47M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) 77.65M 6.57M n/a n/a n/a n/a
Cash remaining 230.47M 301.55M n/a n/a n/a n/a
Runway (months of cash) 4.4 67.4 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
7 Jun 22 Randle Stuart A Common Stock Sell Dispose S No No 283.31 3,014 853.9K 4,320
7 Jun 22 Randle Stuart A Common Stock Option exercise Acquire M No No 78.5 3,014 236.6K 7,334
7 Jun 22 Randle Stuart A Stock Option / Common Stock Option exercise Dispose M No No 78.5 3,014 236.6K 0
3 May 22 Babich George JR Common Stock Grant Acquire A No No 0 520 0 10,960.237
3 May 22 Babich George JR Stock Option / Common Stock Grant Acquire A No No 284.85 969 276.02K 969
3 May 22 Babich George JR Common Stock Grant Acquire A No No 0 520 0 10,960.237
3 May 22 Babich George JR Stock Option / Common Stock Grant Acquire A No No 284.85 969 276.02K 969
3 May 22 Duncan Candace H Common Stock Grant Acquire A No No 0 399 0 3,501.016
3 May 22 Duncan Candace H Stock Option / Common Stock Grant Acquire A No No 284.85 969 276.02K 969
3 May 22 Gretchen R Haggerty Common Stock Grant Acquire A No No 0 399 0 3,578
47.7% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 530 533 -0.6%
Opened positions 69 87 -20.7%
Closed positions 72 74 -2.7%
Increased positions 185 163 +13.5%
Reduced positions 189 190 -0.5%
13F shares Current Prev Q Change
Total value 14.96B 14.17B +5.6%
Total shares 42.18M 43.13M -2.2%
Total puts 76.8K 120.9K -36.5%
Total calls 337.9K 97.8K +245.5%
Total put/call ratio 0.2 1.2 -81.6%
Largest owners Shares Value Change
TROW T. Rowe Price 6.93M $2.46B +6.7%
Vanguard 5.15M $1.83B +1.7%
BLK Blackrock 4.34M $1.54B -10.7%
Wellington Management 3.21M $1.14B -3.9%
STT State Street 1.93M $686.23M -0.9%
JHG Janus Henderson 1.9M $674.2M +10.6%
Atlanta Capital Management Co L L C 1.11M $392.26M +4.4%
American Century Companies 1.07M $380.7M -14.0%
Geode Capital Management 885.75K $313.53M +5.0%
Marshall Wace 678.75K $240.84M +2.1%
Largest transactions Shares Bought/sold Change
BLK Blackrock 4.34M -518.28K -10.7%
Parnassus Investments 0 -486.91K EXIT
Norges Bank 0 -440.22K EXIT
TROW T. Rowe Price 6.93M +432.42K +6.7%
JHG Janus Henderson 1.9M +181.92K +10.6%
American Century Companies 1.07M -174.36K -14.0%
Balyasny Asset Management 202.23K +166.74K +469.7%
Eaton Vance Management 284.64K +166.68K +141.3%
Millennium Management 91.38K -158.97K -63.5%
HBCYF HSBC 42.53K -141.51K -76.9%

Financial report summary

?
Risks
  • Our results of operations and financial condition may be adversely affected by public health epidemics, including the ongoing COVID-19 global health pandemic.
  • Our customers depend on third party coverage and reimbursements, and the failure of healthcare programs to provide sufficient coverage and reimbursement for our medical products could adversely affect us.
  • We are subject to extensive government regulation, which may require us to incur significant expenses to ensure compliance. Our failure to comply with those regulations could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • We are subject to healthcare fraud and abuse laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.
  • We may not be successful in achieving expected operating efficiencies and sustaining or improving operating expense reductions, and may experience business disruptions associated with restructuring, facility consolidations, realignment, cost reduction and other strategic initiatives.
  • A significant portion of our U.S. revenues is derived from sales to distributors, and “destocking” activity by these distributors can adversely affect our revenues and results of operations.
  • We may incur material losses and costs as a result of product liability and warranty claims, as well as product recalls, any of which may adversely affect our results of operations and financial condition. Furthermore, our reputation as a medical device company may be damaged if one or more of our products are, or are alleged to be, defective.
  • Volatility in domestic and global financial markets could adversely impact our results of operations, financial condition and liquidity.
  • Our strategic initiatives, including acquisitions, may not produce the intended growth in revenue and operating income, which could have a material adverse effect on our operating results.
  • Health care reform may have a material adverse effect on our industry and our business.
  • We are subject to risks associated with our non-U.S. operations.
  • Foreign currency exchange rate, commodity price and interest rate fluctuations may adversely affect our results.
  • Fluctuations in our effective tax rate and changes to tax laws may adversely affect us.
  • An interruption in our manufacturing or distribution operations or our supply of raw materials may adversely affect our business.
  • Our ability to attract, train, develop and retain key employees is important to our success.
  • Our failure to maintain strong relationships with physicians and other health care professionals could adversely affect us.
  • Our technology is important to our success, and our failure to protect our intellectual property rights could put us at a competitive disadvantage.
  • Our products or processes may infringe the intellectual property rights of others, which may cause us to pay unexpected litigation costs or damages or prevent us from selling our products.
  • Other pending and future litigation may involve significant costs and adversely affect our business.
  • Our debt agreements impose restrictions on our business, which could prevent us from pursuing business opportunities and taking other desirable corporate actions, and may adversely affect our ability to respond to changes in our business and manage our operations.
  • Under our cross-currency swap agreements, a meaningful decline in the U.S. dollar to euro exchange rate could have a material adverse effect on our cash flows.
  • We may issue additional shares of our common stock or instruments convertible into our common stock, which could cause the price of our common stock to decline.
  • We may not pay dividends on our common stock in the future.
  • Certain provisions of our corporate governing documents, Delaware law and our Senior Notes could discourage, delay, or prevent a merger or acquisition.
Management Discussion
  • Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • Teleflex Incorporated (“we,” “us,” “our" and “Teleflex”) is a global provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products worldwide through a combination of our direct sales force and distributors. Because our products are used in numerous markets and for a variety of procedures, we are not dependent upon any one end-market or procedure. We are focused on achieving consistent, sustainable and profitable growth by increasing our market share and improving our operating efficiencies.
  • We evaluate our portfolio of products and businesses on an ongoing basis to ensure alignment with our overall objectives. Based on our evaluation, we may identify opportunities to divest businesses and product lines that do not meet our objectives. In addition, we may seek to optimize utilization of our facilities through restructuring initiatives designed to further improve our cost structure and enhance our competitive position. We also may continue to explore opportunities to expand the size of our business and improve operating margins through a combination of acquisitions and distributor to direct sales conversions, which generally involve our elimination of a distributor from the sales channel, either by acquiring the distributor or terminating the distributor relationship (in some instances, particularly in Asia, the conversions involve our acquisition or termination of a master distributor and the continued sale of our products through sub-distributors or through new distributors). Distributor to direct sales conversions are designed to facilitate improved product pricing and more direct access to the end users of our products within the sales channel.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: catheter, escalate, France, geopolitical, life, meant, proprietary, staffing, volatility
Removed: adversely, April, beginning, border, decline, emerge, freight, half, high, immunization, largely, lengthened, partial, spend, temporary, travel, treatment, vaccine, work